Form 4: Atara Biotherapeutics Director William Heiden Granted 7,828 Restricted Stock Units

Atara Biotherapeutics, Inc. Director William K. Heiden was granted 7,828 restricted stock units (RSUs) on June 10, 2025, increasing his beneficial ownership to 22,188 shares.

Summary

• William K. Heiden, a Director of Atara Biotherapeutics, Inc. (ATRA), was granted 7,828 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on June 10, 2025, with a reported price of $0 per share, typical for RSU grants.
• Following this acquisition, Mr. Heiden's total beneficial ownership in Atara Biotherapeutics, Inc. stands at 22,188 shares.
• These RSUs are subject to a vesting schedule, which will occur on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, contingent upon Mr. Heiden's continuous service to the company.
• The reported beneficial ownership amount of 22,188 shares reflects the impact of a 1:25 reverse stock split implemented by Atara Biotherapeutics on June 20, 2024.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is generally a positive signal, indicating alignment of interests and retention of key personnel. It's a routine compensation event, not indicative of significant operational changes, but it reinforces governance stability.

Positives

• The grant of 7,828 Restricted Stock Units (RSUs) to Director William K. Heiden aligns his interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• The increase in beneficial ownership to 22,188 shares demonstrates continued commitment from a key director.

Future Outlook

The granted Restricted Stock Units are scheduled to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, contingent on the reporting person's continuous service. This indicates a future commitment period for the director.

Industry Context

This Form 4 filing reports a routine equity compensation grant to a director in the biotechnology sector. Such grants are common practice across industries, including biotech, to incentivize and retain key personnel by aligning their financial interests with the long-term performance of the company. The reverse stock split mentioned is a corporate action that can occur in various industries, often to increase share price and meet listing requirements.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard practice for executive and board compensation across publicly traded companies, including those in the biotechnology and pharmaceutical sectors. This method aligns director incentives with shareholder value creation.
• The vesting schedule, contingent on continuous service, is also a common feature of RSU grants, designed to promote long-term commitment.
• The 1:25 reverse stock split implemented by Atara Biotherapeutics is a corporate action that companies in various industries, including biotech, undertake. For example, companies like Sorrento Therapeutics (SRNE) and Athersys (ATHX) have also executed reverse stock splits to manage share price and maintain exchange listing compliance.

Related Party Transactions

• The grant of 7,828 Restricted Stock Units to William K. Heiden, a Director of Atara Biotherapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, as the value of the compensation is tied to the company's stock performance. It also represents a minor dilution if the RSUs are new issuances upon vesting, though this is standard for equity compensation plans.

Next Steps

• Vesting of the 7,828 Restricted Stock Units on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.

Key Dates

Recommendation

Keywords

Atara Biotherapeutics, ATRA, Form 4, SEC filing, Restricted Stock Units, RSU grant, Director compensation, Insider transaction, Beneficial ownership, William K. Heiden, Biotechnology, Pharmaceuticals, Stock split